ConCallIQ
Go Pro
AJANTPHARM Diversified 15 May 2026

Ajanta Pharma Limited — Q4 FY26

Ajanta Pharma delivered a strong Q4 FY26 with revenue of INR 1,422 crore (+21% YoY) and PAT of INR 267 crore (+18% YoY), driven by stellar US generics growth (+56% YoY) and Afri...

bullish high
Compare with...
Revenue ₹1,422 Cr +21%
EBITDA ₹333 Cr +12%
PAT ₹267 Cr +18%
EBITDA Margin 23%
Duration
Read Time 1 min read

Financial stats pending filing verification

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Middle East conflict impact on costs

Prolonged conflict could increase raw material and freight costs, which management expects to absorb for 2-3 months but may pressure margins beyond.

high · management_commentary
R

US FDA Form 483 at Paithan facility

Five observations received; potential escalation could impact US filings or existing product supplies if not resolved satisfactorily.

medium · analyst_question
R

Asia business recovery uncertainty

Asia declined 10% in Q4 due to logistics disruptions; while management expects high double-digit growth, demand normalization is unproven.

medium · data_observation
R

Promoter pledge increase

Pledge by two promoter brothers for unrelated businesses has risen; though management says it's not company-related, it could signal personal financial stress.

low · analyst_question